左室射血分数保留的心力衰竭的研究进展
Progress in the Study of Heart Failure with Left Ventricular Ejection Fraction Retention
DOI: 10.12677/ACM.2019.92020, PDF,   
作者: 邵淑梅, 谷秀娟：延安大学附属医院，陕西 延安；韩肖肖：西安市妇幼保健院，陕西 西安
关键词: 射血分数保留；心力衰竭；病理生理；生物标志物；Ejection Fraction Retention； Heart Failure； Pathophysiology； Biomarkers
摘要: 左室射血分数保留的心力衰竭(HFpEF)是左室射血分数正常或接近正常(LVEF ≥ 50%)的心力衰竭。HFpEF与射血分数降低的心力衰竭(HFrEF)相比有相似的发病率和病死率。该文主要介绍HFpEF的病理生理机制和生物标志物在诊断及预后评估中的进展。
Abstract: Heart failure with preserved left ventricular ejection fraction (HFpEF) is a heart failure with normal or near normal left ventricular ejection fraction (LVEF < 50%). HFpEF has similar morbidity and mortality as heart failure (HFrEF) with reduced ejection fraction. This article mainly introduces the pathophysiological mechanism of HFpEF and the progress of biomarkers in diagnosis and prognosis evaluation.
文章引用：邵淑梅, 韩肖肖, 谷秀娟. 左室射血分数保留的心力衰竭的研究进展[J]. 临床医学进展, 2019, 9(2): 121-126. https://doi.org/10.12677/ACM.2019.92020

参考文献

[1] Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200. [Google Scholar] [CrossRef] [PubMed]
[2] Lam, C.S., Roger, V.L., Rodeheller, R.J., et al. (2007) Cardiac Structure and Ventricular-Vascular Function in Persons with Heart Failure and Preserved Ejection Fraction from Olmsted County. Minnesota. Circulation, 115, 1982-1990. [Google Scholar] [CrossRef] 
[3] 周鹍, 逯金金, 林谦. 舒张性心力衰竭研究进展[J]. 中西医结合心脑血管病杂志, 2015(13): 20-22.
[4] Lubine, E., De Maria, A., Krishnoswamy, P., et al. (2002) Utility of Bnatrinretie Peptide in Detecting Diastolic Dysfunction. Circulation, 105, 595-601.
[5] 郭继鸿. 舒张性心衰的新理念[J]. 临床心电学杂志, 2009, 18(3): 209-221.
[6] Massie, B.M., Carson, P.E., MeMurry, J.J., et al. (2008) Irheganm in Patients with Heart Failure and Preserved Ejection Fraction. The New England Journal of Medicine, 359, 2456-2467.
[7] Coletta, A.P., Cullington, D., Clark, A.L. and Cleland, J.G.F. (2008) Clinical Trials Update from European Society of Cardiology Meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF and HOME-HF. Euro-pean Journal of Heart Failure, 10, 1264-1267. [Google Scholar] [CrossRef] [PubMed]
[8] von Haehling, S., Jankowska, E.A., Morgenthaler, N.G., et al. (2007) Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 50, 1973-1980. [Google Scholar] [CrossRef] [PubMed]
[9] 张晓伟, 刘广忠, 李悦. 心衰生物标记物研究新进展[J]. 现代生物医学进展, 2015, 15(3): 558-561.
[10] Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Kardiologia Polska, 74, 1037-1147. [Google Scholar] [CrossRef] 
[11] Holwerda, D. (1972) A Glyeopeptide from the Posterior Lobe of Pig Pituitaries I Isolation and Characterization. European Journal of Biochemistry, 28, 334-339. [Google Scholar] [CrossRef] [PubMed]
[12] Dobša, L. and Cullen Edozien, K. (2013) Copeptin and Its Potential Role in Diagnosis and Prognosis of Various Diseases. Biochemia Medica, 23, 172-190. [Google Scholar] [CrossRef] 
[13] Torre-Amione, G. (2005) Immune Activation in Chronic Heart Failure. The American Journal of Cardiology, 95, 3-8. [Google Scholar] [CrossRef] [PubMed]
[14] Campbell, D.J., Woodward, M., Chalmers, J.P., et al. (2005) Prediction of Heart Failure by Amino Terminal-pro-B-type Natriuretic Peptide and C-Reactive Protein in Subjects with Cerebrovascular Disease. Hypertension, 45, 69-74. [Google Scholar] [CrossRef] 
[15] Ishikawa, C., Tsutamoto, T., Fujii, M., et al. (2006) Prediction of Mortality by High-Sensitivity C-Reactive Protein and Brain Natriuretic Peptide in Patients with Dilated Cardiomyopathy. Circulation Journal, 70, 857-863.
[16] Nikolic, V.N., Jevtovic-Stoimenov, T., Stokanovic, D., et al. (2013) An Inverse Correlation between TNF-Alpha Serum Levels and Heart Rate Variability in Patients with Heart Failure. Journal of Cardiology, 62, 37-43. [Google Scholar] [CrossRef] [PubMed]
[17] Tsarouhas, K., Tsitsimpikou, C., Haliassos, A., et al. (2011) Study of Insulin Resistance, TNF-Alpha, Total Antioxidant Capacity and Lipid Profile in Patients with Chronic Heart Failure under Exercise. In Vivo, 25, 1031-1037.
[18] 侯媛媛, 王志娟. 肿瘤坏死因子检测在心衰患者中的临床意义[J]. 福建医药杂志, 2004, 26(2): 112.
[19] Hrynchyshyn, N., Jourdain, P., Desnos, M., et al. (2013) Galectin-3: A New Bi-omarker for the Diagnosis, Analysis and Prognosis of Acute and Chronic Heart Failure. Archives of Cardiovascular Diseases, 106, 541-546. [Google Scholar] [CrossRef] [PubMed]
[20] Morrow, D.A. and O’Donoghue, M.L. (2012) Galectin-3 in Car-diovascular Disease: A Possible Window into Early Myocardial Firosis. Journal of the American College of Cardiology, 60, 1257-1258. [Google Scholar] [CrossRef] [PubMed]
[21] de Boer, R.A., Lok, D.J., Jaarsma, T., et al. (2011) Predictive Value of Plasma Galectin-3 Levels in Heart Failure with Reduced and Preserved Ejection Fraction. Annals of Medicine, 43, 60-68. [Google Scholar] [CrossRef] [PubMed]
[22] Motiwala, S.R., Szymonifka, J., Belcher, A., et al. (2013) Serial Measurement of Galectin-3 in Patients with Chronic Heart Failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. European Journal of Heart Failure, 15, 1157-1163. [Google Scholar] [CrossRef] [PubMed]
[23] Wu, A.H., Wians, F. and Jaffe, A. (2013) Biological Variation of Ga-lectine-3 and Soluble ST2 for Chronic Heart Failure: Implication on Interpretation of Test Results. American Heart Journal, 165, 995-999. [Google Scholar] [CrossRef] [PubMed]
[24] Yin, Q.S., Shi, B., Dong, L., et al. (2014) Comparative Study of Galectin-3 and B-Type Natriuretic Peptide as Biomarkers for the Diagnosis of Heart Failure. Journal of Geriatric Car-diology, 11, 79-82.
[25] Dupont, M., Wu, Y., Hazen, S.L., et al. (2012) Cystatin C Identifies Patients with Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. Circulation Heart Failure, 5, 602-609. [Google Scholar] [CrossRef] 
[26] Yan, Y. (2010) The Mechanism of Coronary Artery Ectasia and Endothelial Protection of Growth Differentiation Factor-15. Chinese Peking Union Medical College, Beijing.
[27] Xu, X., Li, Z. and Gao, W. (2011) Growth Differentiation Factor 15 in Cardiovascular Diseases: From Bench to Bedside. Biomarkers, 16, 466-475. [Google Scholar] [CrossRef] 
[28] Baessler, A., Strack, C., Rousseva, E., et al. (2012) Growth-Differentiation Factor-15 Improves Reclassification for the Diagnosis of Heart Failure with Normal Ejection Fraction in Morbid Obesity. European Journal of Heart Failure, 14, 1240-1248. [Google Scholar] [CrossRef] [PubMed]

为你推荐